JP2010070565A5 - - Google Patents

Download PDF

Info

Publication number
JP2010070565A5
JP2010070565A5 JP2009293390A JP2009293390A JP2010070565A5 JP 2010070565 A5 JP2010070565 A5 JP 2010070565A5 JP 2009293390 A JP2009293390 A JP 2009293390A JP 2009293390 A JP2009293390 A JP 2009293390A JP 2010070565 A5 JP2010070565 A5 JP 2010070565A5
Authority
JP
Japan
Prior art keywords
combination according
combination
drug
vector
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009293390A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010070565A (ja
Filing date
Publication date
Priority claimed from US08/889,355 external-priority patent/US7002027B1/en
Application filed filed Critical
Publication of JP2010070565A publication Critical patent/JP2010070565A/ja
Publication of JP2010070565A5 publication Critical patent/JP2010070565A5/ja
Withdrawn legal-status Critical Current

Links

JP2009293390A 1997-07-08 2009-12-24 治療用薬剤の細胞への送達を増強するための組成物および方法 Withdrawn JP2010070565A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/889,355 US7002027B1 (en) 1996-01-08 1997-07-08 Compositions and methods for therapeutic use

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000501781A Division JP4460148B2 (ja) 1997-07-08 1998-07-08 治療用薬剤の細胞への送達を増強するための組成物および方法

Publications (2)

Publication Number Publication Date
JP2010070565A JP2010070565A (ja) 2010-04-02
JP2010070565A5 true JP2010070565A5 (https=) 2011-02-10

Family

ID=25394956

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000501781A Expired - Fee Related JP4460148B2 (ja) 1997-07-08 1998-07-08 治療用薬剤の細胞への送達を増強するための組成物および方法
JP2009293390A Withdrawn JP2010070565A (ja) 1997-07-08 2009-12-24 治療用薬剤の細胞への送達を増強するための組成物および方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000501781A Expired - Fee Related JP4460148B2 (ja) 1997-07-08 1998-07-08 治療用薬剤の細胞への送達を増強するための組成物および方法

Country Status (20)

Country Link
US (3) US7002027B1 (https=)
EP (2) EP2106807B1 (https=)
JP (2) JP4460148B2 (https=)
KR (1) KR100691572B1 (https=)
AR (1) AR016312A1 (https=)
AT (2) ATE434448T1 (https=)
AU (1) AU774338B2 (https=)
CA (1) CA2294709C (https=)
CY (1) CY1109367T1 (https=)
DE (2) DE69840932D1 (https=)
DK (1) DK1011733T3 (https=)
ES (2) ES2328094T3 (https=)
HU (1) HUP0002683A3 (https=)
IL (1) IL133929A0 (https=)
MY (1) MY138257A (https=)
NZ (1) NZ502060A (https=)
PT (1) PT1011733E (https=)
TW (1) TW490306B (https=)
WO (1) WO1999002191A1 (https=)
ZA (1) ZA986003B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US7002027B1 (en) * 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
EP1070047A2 (en) 1998-04-08 2001-01-24 Celltech Chiroscience Limited Lipids
ES2745068T3 (es) * 2001-12-20 2020-02-27 Merck Sharp & Dohme Composiciones de SYN3 y métodos
JP2007526219A (ja) * 2003-06-04 2007-09-13 カンジ，インコーポレイテッド トランスフェクション薬剤
US7355056B2 (en) * 2003-06-04 2008-04-08 Canji, Inc. Transfection agents
US7790039B2 (en) * 2003-11-24 2010-09-07 Northwest Biotherapeutics, Inc. Tangential flow filtration devices and methods for stem cell enrichment
CA2548100C (en) * 2003-12-10 2015-03-24 Canji, Inc. Methods and compositions for treatment of interferon-resistant tumors
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US8716021B2 (en) * 2005-09-07 2014-05-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of replicators to prevent gene silencing
US20110071100A1 (en) * 2008-05-05 2011-03-24 Tiltan Pharma Ltd. Sulfobetaines for cancer, obesity, macular degeneration, neurodegenerative diseases
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
US20120147800A1 (en) * 2010-12-10 2012-06-14 Minyoung Park Power management in a wireless network having stations with different power capabilities
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US10492104B2 (en) * 2016-03-10 2019-11-26 Cable Television Laboratories, Inc. Latency reduction in wireless service
WO2026077967A1 (en) 2024-10-08 2026-04-16 Ferring International Center Sa Method for making syn3

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554386A (en) 1986-07-03 1996-09-10 Advanced Magnetics, Inc. Delivery of therapeutic agents to receptors using polysaccharides
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6207454B1 (en) 1989-10-16 2001-03-27 Amgen Inc. Method for enhancing the effciency of gene transfer with stem cell factor (SCF) polypeptide
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5120316A (en) 1990-09-28 1992-06-09 Akzo N.V. Urethral catheter and catheterization process
WO1992006180A1 (en) 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
NZ240846A (en) * 1990-12-06 1994-04-27 Hoechst Ag Dimeric bile acid derivatives; preparatory processes and pharmaceutical compositions
DE69233725T2 (de) 1991-06-28 2009-02-12 The Regents Of The University Of Michigan, Ann Arbor Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren
JPH06509578A (ja) 1991-07-26 1994-10-27 ユニバーシティ・オブ・ロチェスター 悪性細胞利用による癌治療法
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
US5521291A (en) 1991-09-30 1996-05-28 Boehringer Ingelheim International, Gmbh Conjugates for introducing nucleic acid into higher eucaryotic cells
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
US5602023A (en) 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
DK0636028T3 (da) 1992-04-03 2004-07-12 Univ California Selvorganiserende polynucleotidleveringssystem omfattende et amfipatisk kationisk peptid
JPH07505773A (ja) 1992-04-03 1995-06-29 ヤング　アレキサンダー　ティー 標的化されたウイルスベクターを用いた遺伝子治療
US5334761A (en) 1992-08-28 1994-08-02 Life Technologies, Inc. Cationic lipids
WO1994006923A1 (en) 1992-09-24 1994-03-31 The University Of Connecticut Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells
US5656609A (en) 1992-09-24 1997-08-12 University Of Connecticut Method of enhancing and/or prolonging expression of gene introduced into a cell using colchicine
US5346701A (en) 1993-02-22 1994-09-13 Theratech, Inc. Transmucosal delivery of macromolecular drugs
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5804566A (en) * 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
JPH07109983A (ja) 1993-10-13 1995-04-25 Nippondenso Co Ltd スクロール型圧縮機
DE69431959T2 (de) 1993-10-15 2003-11-06 Cytrx Corp Therapeutische abgabesysteme und verfahren für ihre verwendung
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
EP1637608B1 (en) 1993-10-25 2009-07-22 CANJI, Inc. Recombinant adenoviral vector and methods of use
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
US5552309A (en) 1994-09-30 1996-09-03 Indiana University Foundation Use of polyols for improving the introduction of genetic material into cells
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
AU6600396A (en) * 1995-07-28 1997-02-26 David E. Kohne Method for enhancing chemiluminescence
US5789244A (en) 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US20040014709A1 (en) 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US5671110A (en) 1996-01-23 1997-09-23 Oneac Corporation Ground skew protection method and apparatus
US6283940B1 (en) * 1997-08-29 2001-09-04 S. Grant Mulholland Catheter
US6938069B1 (en) * 2000-03-18 2005-08-30 Computing Services Support Solutions Electronic meeting center
ES2745068T3 (es) 2001-12-20 2020-02-27 Merck Sharp & Dohme Composiciones de SYN3 y métodos
KR100499787B1 (ko) 2002-11-29 2005-07-07 인티그런트 테크놀로지즈(주) 스위치 모드 동작을 하는 선형성이 우수한 광대역 가변이득 증폭기
JP2007526219A (ja) 2003-06-04 2007-09-13 カンジ，インコーポレイテッド トランスフェクション薬剤
US7355056B2 (en) 2003-06-04 2008-04-08 Canji, Inc. Transfection agents
WO2004108898A2 (en) 2003-06-04 2004-12-16 Canji, Inc. Transfection agents
CA2548100C (en) 2003-12-10 2015-03-24 Canji, Inc. Methods and compositions for treatment of interferon-resistant tumors

Similar Documents

Publication Publication Date Title
JP2010070565A5 (https=)
Ito et al. DNA/polyethyleneimine/hyaluronic acid small complex particles and tumor suppression in mice
Schiedner et al. Selective depletion or blockade of Kupffer cells leads to enhanced and prolonged hepatic transgene expression using high-capacity adenoviral vectors
EP1987845B1 (en) Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor.
JP2005534648A5 (https=)
JP2021507687A5 (https=)
JP2006508918A (ja) 修飾されたアシアロインターフェロンおよびその使用
JP2008106072A (ja) 固型腫瘍、乳頭腫および疣贅の遺伝子治療
Minter et al. Adenoviral delivery of human and viral IL-10 in murine sepsis
CN1596130A (zh) 治疗神经退行性疾病的基因治疗药物
Okamoto et al. Chitosan–interferon-β gene complex powder for inhalation treatment of lung metastasis in mice
JP6966755B2 (ja) 組換え発現ベクター及び当該ベクターを封入した脂質膜構造体
JP2001509492A5 (https=)
CN1893981A (zh) 用于治疗干扰素耐药性肿瘤的方法和组合物
WO2021042944A1 (zh) 肌肉靶向的微环dna基因治疗
JP2003501107A (ja) 特異的ヨウ素輸送体（ｎｉｓ）をコードする組換えアデノウイルス
Hillman et al. Tumor irradiation followed by intratumoral cytokine gene therapy for murine renal adenocarcinoma
Sun et al. Genetically engineered recombinant adenovirus expressing interleukin‑2 for hepatocellular carcinoma therapy
CN100342019C (zh) 用编码分泌蛋白质如干扰素－β的基因进行治疗的方法和组合物
Cheng et al. Combined delivery of IL12 and an IL18 mutant without IL18BP-binding activity by an adenoviral vector enhances tumor specific immunity
Miyakawa et al. Prolonged circulation half-life of interferon γ activity by gene delivery of interferon γ–serum albumin fusion protein in mice
EP3697431A1 (en) Treatment of neuropathy with dna construct expressing hgf isoforms with reduced interference from gabapentinoids
EP1442750B1 (en) Treatment of cancer using cytokine-expressing polynucleotides and compositions therefor
CN117899223A (zh) 以nup35基因和或以nup35蛋白作为作用靶点的物质的应用及组合物
EP4630562A1 (en) Nucleic acid based cancer vaccine and methods thereof